The move would add another barrier for parents who want to vaccinate healthy children ahead of the respiratory virus season.

Novavax ( ($NVAX) ) has risen by 19.30%. Read on to learn why. Novavax has seen a remarkable 19.30% increase in its stock price over the past ...

“We’ve stepped back into the world that we lived in before the [CDC’s vaccine advisory committee] was created,” said Dr.

Drastic changes are brewing at the FDA, as newly appointed Commissioner Dr. Marty Makary indicates a shift toward stricter scientific accountability in vaccine approvals. In a notable departure from ...

The U.S. Food and Drug Administration may not renew its authorization for Pfizer's COVID-19 vaccine approved for children ...

Q2 2025 Earnings Call Transcript August 6, 2025 Novavax, Inc. beats earnings expectations. Reported EPS is $0.601, ...

Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine makers after rival Moderna reported disappointing Q2 results.

The Plot Against Vaccines Robert F. Kennedy Jr. and his allies have hit on a way to undermine immunization. Kiera Butler and Anna Merlan September+October 2025 Issue ...

(RTTNews) - Novavax, Inc. (NVAX) Thursday said that its H5N1 avian pandemic influenza vaccine candidate induced robust immune responses in nonhuman primates.

Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose administration Potential for single ...

Peer-reviewed data shows Novavax's H5N1 vaccine candidate demonstrated immunogenicity against currently circulating variants following either single or two-dose administration Potential for single ...